Market Place
Sourcing Support
All News #Library
Biotech
Nuvalent Presents Neladalkib Data in Advanced NSCLC at 2026 ASCO
21 Apr 2026 //
PR NEWSWIRE
Nuvalent To Unveil Zidesamtinib Data At AACR 2026 Meeting
18 Mar 2026 //
PR NEWSWIRE
Nuvalent Advances Ontarget 2026 Plan, Highlights Key Milestones
12 Jan 2026 //
PR NEWSWIRE
Nuvalent To Present At J.P. Morgan Healthcare Conference
22 Dec 2025 //
PR NEWSWIRE BIO
Nuvalent Appoints Ron Squarer To Board Of Directors
10 Dec 2025 //
PR NEWSWIRE
Nuvalent`s Zidesamtinib NDA Accepted By FDA For Ros1+ NSCLC
20 Nov 2025 //
PR NEWSWIRE
Nuvalent Announces Positive ALKOVE-1 Data for Neladalkib
17 Nov 2025 //
PR NEWSWIRE
Nuvalent Announces Public Offering Of Common Stock
17 Nov 2025 //
PR NEWSWIRE
Nuvalent To Present Patient-Reported Outcomes From Zidesamtinib
05 Nov 2025 //
PR NEWSWIRE
Nuvalent Updates Pipeline Progress And Q3 2025 Results
30 Oct 2025 //
PR NEWSWIRE
Nuvalent Unveils Neladalkib Data In Advanced ALK +ve Solid Tumors
18 Oct 2025 //
PR NEWSWIRE
Nuvalent to Present at Cantor Global Healthcare Conference 2025
28 Aug 2025 //
PR NEWSWIRE
Nuvalent`s ARROS-1 Data on Zidesamtinib for ROS1-positive NSCLC
13 Aug 2025 //
PR NEWSWIRE
Nuvalent Reports Second Quarter 2025 Financial Results
08 Aug 2025 //
PR NEWSWIRE
Nuvalent Begins ALKAZAR Phase 3 Trial for NSCLC Patients
21 Jul 2025 //
PR NEWSWIRE
Nuvalent Updates Pipeline, Business Progress, and Q1 2025 Results
08 May 2025 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.